Market Research Logo

Hypoparathyroidism - Pipeline Review, H1 2018

Hypoparathyroidism - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Pipeline Review, H1 2018, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.

Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 4 respectively.

Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Hypoparathyroidism - Overview
Hypoparathyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypoparathyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoparathyroidism - Companies Involved in Therapeutics Development
Ascendis Pharma A/S
Chugai Pharmaceutical Co Ltd
Eli Lilly and Co
Entera Bio Ltd
GC Pharma
Shire Plc
Hypoparathyroidism - Drug Profiles
ACP-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-612 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-6272K - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
parathyroid hormone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCO-371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem cell Therapy for Hypoparathyroidism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypoparathyroidism - Dormant Projects
Hypoparathyroidism - Product Development Milestones
Featured News & Press Releases
May 07, 2018: Ascendis Pharma Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology
Apr 09, 2018: Shire’s Natpar Rejects For Use Within NHS Scotland
Mar 20, 2018: New Data Presented at the Endocrine Society’s 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism
Mar 19, 2018: Ascendis Pharma Announces Posters on Rare Disease Pipeline Programs at ENDO 2018
Mar 12, 2018: Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society’s 2018 Annual Meeting
Jan 08, 2018: Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTH
Sep 26, 2017: Ascendis Pharma Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH
Sep 05, 2017: Ascendis Pharma Announces Presentations on TransCon PTH at Upcoming Medical Conferences
May 19, 2017: Shire to highlight new research into chronic hypoparathyroidism at the European Congress of Endocrinology
Apr 26, 2017: Shire Granted EU Conditional Marketing Authorisation for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism
Apr 03, 2017: Ascendis Pharma Presents Data on TransCon PTH at ENDO 2017
Feb 28, 2017: Ascendis Pharma Announces Data on TransCon PTH at ENDO 2017
Feb 24, 2017: First hormone replacement therapy for parathyroid disorder
Jun 29, 2016: EnteraBio Receives Orphan Drug Approval for PTH 1-34 from European Medicines Agency
Jul 22, 2015: Entera Bio Announces Phase II Results of PTH 1-34 in Treating Hypoparathyroidism
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hypoparathyroidism, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hypoparathyroidism - Pipeline by Ascendis Pharma A/S, H1 2018
Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Hypoparathyroidism - Pipeline by Eli Lilly and Co, H1 2018
Hypoparathyroidism - Pipeline by Entera Bio Ltd, H1 2018
Hypoparathyroidism - Pipeline by GC Pharma, H1 2018
Hypoparathyroidism - Pipeline by Shire Plc, H1 2018
Hypoparathyroidism - Dormant Projects, H1 2018
List of Figures
Number of Products under Development for Hypoparathyroidism, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report